SMMT — Summit Therapeutics Inc.
$15.47-0.51%
Last close: · regular session
Last 60 sessions
SMMT closed at $15.47 (-0.51%) on Oct 23, 2026. Active automatic shelf (S-3ASR, Jun 2026). Float: 103.0M shares. Latest SEC filing: 8-K on Sep 29, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SMMT in the TickerWise workspace.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 159
- Website: https://www.summittxinc.com
Latest SEC filings for SMMT
Latest SMMT news
- Summit Therapeutics reports survival benefit for cancer drug in trial Read article
- Summit Expands Ivonescimab Development Into Biliary Tract Cancer Read article
- Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? Read article
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos Read article
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics Read article
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Read article
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types Read article
- Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – What’s Next? Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.